The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein ...

PHILADELPHIA, PA — Vittoria Biotherapeutics will present groundbreaking research on its innovative Senza5™ platform at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, ...

Vittoria Biotherapeutics, Inc ., a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced the successful ...

Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies ...

VIPER-101 leverages the company’s proprietary Senza5 TM platform technology, which enhances T cell effector function by abrogating CD5-mediated immunosuppression through gene editing.